Breaking News Instant updates and real-time market news.

IEA

Infrastructure and Energy Alternatives

$2.38 /

+0.1 (+4.39%)

07:45
06/11/20
06/11
07:45
06/11/20
07:45

Infrastructure and Energy Alternatives upgraded to Buy from Neutral at DA Davidson

DA Davidson analyst Brent Thielman upgraded Infrastructure and Energy Alternatives to Buy from Neutral with a price target of $5.50, up from $3.50. The activity and demand for renewables construction is "strong" an the company's 2021 prospects are on the rise, the analyst tells investors in a research note. Thielman adds that while the capital structure complexity is a "material overhang", the corporate management additions and achievable 2020 guidance gives him greater confidence in Infrastructure and Energy Alternatives shares.

IEA Infrastructure and Energy Alternatives
$2.38 /

+0.1 (+4.39%)

06/11/20 DA Davidson
Infrastructure and Energy Alternatives upgraded to Buy at DA Davidson

TODAY'S FREE FLY STORIES

Periodicals
Delta Air Lines may avoid involuntary furlougs this fall, Reuters says » 20:08
07/13/20
07/13
20:08
07/13/20
20:08
DAL

Delta Air Lines

$27.15 /

+0.05 (+0.18%)

Delta Air Lines has…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
DAL Delta Air Lines
$27.15 /

+0.05 (+0.18%)

DAL Delta Air Lines
$27.15 /

+0.05 (+0.18%)

07/09/20 Citi
Citi sees expectations for corporate travel rebound all but evaporating
06/29/20 Goldman Sachs
Delta Air Lines price target raised to $38 from $33 at Goldman Sachs
06/16/20 Stifel
United loyalty deal raises odds of survival without restructuring, says Stifel
06/10/20 JPMorgan
Delta Air Lines price target lowered to $41 from $45 at JPMorgan
DAL Delta Air Lines
$27.15 /

+0.05 (+0.18%)

DAL Delta Air Lines
$27.15 /

+0.05 (+0.18%)

DAL Delta Air Lines
$27.15 /

+0.05 (+0.18%)

DAL Delta Air Lines
$27.15 /

+0.05 (+0.18%)

Earnings
Ryerson sees Q2 revenue $765M-$775M, consensus $761.4M. » 20:05
07/13/20
07/13
20:05
07/13/20
20:05
RYI

Ryerson

$5.30 /

-0.07 (-1.30%)

Sees Q2 adj. EBITDA…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
RYI Ryerson
$5.30 /

-0.07 (-1.30%)

RYI Ryerson
$5.30 /

-0.07 (-1.30%)

05/20/20 BMO Capital
Ryerson price target lowered to $6 from $9 at BMO Capital
08/26/19 BMO Capital
Ryerson price target lowered to $7 from $9 at BMO Capital
RYI Ryerson
$5.30 /

-0.07 (-1.30%)

Recommendations
Edwards Lifesciences patent settlement removes overhang, says Piper Sandler » 20:00
07/13/20
07/13
20:00
07/13/20
20:00
EW

Edwards Lifesciences

$67.18 /

-0.67 (-0.99%)

, ABT

Abbott

$93.13 /

+0.09 (+0.10%)

Piper Sandler analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
EW Edwards Lifesciences
$67.18 /

-0.67 (-0.99%)

ABT Abbott
$93.13 /

+0.09 (+0.10%)

EW Edwards Lifesciences
$67.18 /

-0.67 (-0.99%)

06/05/20 Piper Sandler
Post points to Edwards resuming recruiting for CLASP trial, says Piper Sandler
04/28/20 Wells Fargo
Edwards Lifesciences downgraded on sales growth gap at Wells Fargo
04/28/20 Wells Fargo
Edwards Lifesciences downgraded to Equal Weight from Overweight at Wells Fargo
04/27/20 Barclays
Edwards Lifesciences price target lowered to $155 from $165 at Barclays
ABT Abbott
$93.13 /

+0.09 (+0.10%)

07/01/20 Lake Street
Lake Street says Tandem pact with Abbott, coverage news both 'very positive'
06/15/20 Piper Sandler
Abbott approval narrows competitive gap to DexCom, says Piper Sandler
06/11/20 UBS
Abbott's COVID-19 testing positive contributor, says UBS
06/09/20 Barrington
Surmodics price target raised to $62 from $56 at Barrington
EW Edwards Lifesciences
$67.18 /

-0.67 (-0.99%)

ABT Abbott
$93.13 /

+0.09 (+0.10%)

EW Edwards Lifesciences
$67.18 /

-0.67 (-0.99%)

ABT Abbott
$93.13 /

+0.09 (+0.10%)

EW Edwards Lifesciences
$67.18 /

-0.67 (-0.99%)

ABT Abbott
$93.13 /

+0.09 (+0.10%)

ABT Abbott
$93.13 /

+0.09 (+0.10%)

Hot Stocks
Biogen initiates new phase 3 study of BAN2401 in preclinical AD » 19:36
07/13/20
07/13
19:36
07/13/20
19:36
BIIB

Biogen

$276.34 /

-2.71 (-0.97%)

, ESALY

Eisai

$0.00 /

+ (+0.00%)

The Alzheimer's…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
BIIB Biogen
$276.34 /

-2.71 (-0.97%)

ESALY Eisai
$0.00 /

+ (+0.00%)

BIIB Biogen
$276.34 /

-2.71 (-0.97%)

07:06 Today Goldman Sachs
Biogen price target lowered to $257 from $300 at Goldman Sachs
07/08/20 Credit Suisse
Biogen submits Aducanumab BLA, upside possible near-term, says Credit Suisse
07/08/20 Stifel
Biogen submission of Aducanumab BLA 'an incremental positive,' says Stifel
07/08/20 Goldman Sachs
Goldman says Biogen BLA submission for Alzheimer's drug an incremental positive
ESALY Eisai
$0.00 /

+ (+0.00%)

10/24/19 Nomura Instinet
Eisai upgraded to Buy from Neutral at Nomura Instinet
09/24/19 Jefferies
Eisai initiated with a Buy at Jefferies
09/17/19 Daiwa
Eisai downgraded to Sell from Neutral at Daiwa
08/05/19 Citi
Eisai upgraded to Neutral from Sell at Citi
BIIB Biogen
$276.34 /

-2.71 (-0.97%)

BIIB Biogen
$276.34 /

-2.71 (-0.97%)

BIIB Biogen
$276.34 /

-2.71 (-0.97%)

BIIB Biogen
$276.34 /

-2.71 (-0.97%)

Periodicals
SoftBank may list Arm Holdings in IPO as soon as 2021, Bloomberg says » 19:27
07/13/20
07/13
19:27
07/13/20
19:27
SFTBY

SoftBank

$0.00 /

+ (+0.00%)

, GS

Goldman Sachs

$208.93 /

+3.33 (+1.62%)

In a follow-up to an…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SFTBY SoftBank
$0.00 /

+ (+0.00%)

GS Goldman Sachs
$208.93 /

+3.33 (+1.62%)

SFTBY SoftBank
$0.00 /

+ (+0.00%)

07/10/20 Nomura Instinet
SoftBank price target raised to 7,240 yen from 6,640 yen at Nomura Instinet
05/26/20 Citi
SoftBank price target lowered to 7,100 yen from 8,200 yen at Citi
03/24/20 Jefferies
SoftBank upgraded to Buy from Hold at Jefferies
02/13/20 HSBC
SoftBank price target raised to 7,000 yen after Sprint deal approval
GS Goldman Sachs
$208.93 /

+3.33 (+1.62%)

07/08/20 Seaport Global
Goldman Sachs initiated with a Buy at Seaport Global
06/26/20 Morgan Stanley
Morgan Stanley sees dividend cuts at Wells Fargo, Capital One after stress tests
06/05/20 Wells Fargo
Goldman Sachs price target raised to $255 from $230 at Wells Fargo
06/04/20
Fly Intel: Top five analyst downgrades
GS Goldman Sachs
$208.93 /

+3.33 (+1.62%)

SFTBY SoftBank
$0.00 /

+ (+0.00%)

GS Goldman Sachs
$208.93 /

+3.33 (+1.62%)

SFTBY SoftBank
$0.00 /

+ (+0.00%)

GS Goldman Sachs
$208.93 /

+3.33 (+1.62%)

GS Goldman Sachs
$208.93 /

+3.33 (+1.62%)

Periodicals
U.S. official says COVID-19 vaccine output to start by end of summer, CNBC says » 19:22
07/13/20
07/13
19:22
07/13/20
19:22
BNTX

BioNTech

$77.73 /

+7.315 (+10.39%)

, PFE

Pfizer

$35.22 /

+1.38 (+4.08%)

, INO

Inovio

$25.57 /

+2.21 (+9.46%)

, JNJ

Johnson & Johnson

$145.30 /

+2.85 (+2.00%)

, MRNA

Moderna

$71.72 /

+9.15 (+14.62%)

, SPY

SPDR S&P 500 ETF Trust

$314.80 /

-2.81 (-0.88%)

, SPX

S&P 500

$0.00 /

+ (+0.00%)

, NVAX

Novavax

$104.46 /

+10.1 (+10.70%)

, MRK

Merck

$77.38 /

+0.64 (+0.83%)

, SNY

Sanofi

$50.96 /

+0.64 (+1.27%)

, GSK

GlaxoSmithKline

$40.07 /

+0.16 (+0.40%)

A senior Trump…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
BNTX BioNTech
$77.73 /

+7.315 (+10.39%)

PFE Pfizer
$35.22 /

+1.38 (+4.08%)

INO Inovio
$25.57 /

+2.21 (+9.46%)

JNJ Johnson & Johnson
$145.30 /

+2.85 (+2.00%)

MRNA Moderna
$71.72 /

+9.15 (+14.62%)

SPY SPDR S&P 500 ETF Trust
$314.80 /

-2.81 (-0.88%)

SPX S&P 500
$0.00 /

+ (+0.00%)

NVAX Novavax
$104.46 /

+10.1 (+10.70%)

MRK Merck
$77.38 /

+0.64 (+0.83%)

SNY Sanofi
$50.96 /

+0.64 (+1.27%)

GSK GlaxoSmithKline
$40.07 /

+0.16 (+0.40%)

BNTX BioNTech
$77.73 /

+7.315 (+10.39%)

09:45 Today Canaccord
BioNTech price target raised to $75 from $60 at Canaccord
07/02/20 B. Riley FBR
Novavax should be bought on weakness from Pfizer data, says B. Riley FBR
07/02/20 BMO Capital
Moderna mRNA platform supported by Pfizer vaccine data, says BMO Capital
07/02/20 SVB Leerink
BioNTech price target raised to $42 from $37 at SVB Leerink
PFE Pfizer
$35.22 /

+1.38 (+4.08%)

09:45 Today Canaccord
BioNTech price target raised to $75 from $60 at Canaccord
07/08/20 Piper Sandler
Opko Health price target raised to $6 from $4 at Piper Sandler
07/08/20 Argus
Pfizer positioned for stronger revenue growth in 2021 and beyond, says Argus
07/07/20 Needham
Vaxcyte initiated with a Buy at Needham
INO Inovio
$25.57 /

+2.21 (+9.46%)

07/01/20
Fly Intel: Top five analyst downgrades
07/01/20 Maxim
Inovio downgraded to Hold from Buy at Maxim
07/01/20 Roth Capital
Roth 'unimpressed' with Inovio data, downgrades to Sell with $11 target
07/01/20 Maxim
Inovio downgraded to Hold from Buy at Maxim
JNJ Johnson & Johnson
$145.30 /

+2.85 (+2.00%)

16:13 Today Oppenheimer
Relmada Therapeutics initiated with an Outperform at Oppenheimer
08:42 Today H.C. Wainwright
Pacira price target raised to $68 from $63 at H.C. Wainwright
07/10/20 Jefferies
Pacira price target raised to $69 from $53 at Jefferies
07/06/20 Baird
Cooper Companies downgraded to Neutral, Baird see confluence of issues
MRNA Moderna
$71.72 /

+9.15 (+14.62%)

07:58 Today Brookline
Moderna initiated with a Buy at Brookline
06:10 Today Jefferies
Jefferies starts Moderna with Buy rating, $90 price target
07/08/20 Piper Sandler
Piper reiterates $100 target on Moderna after Phase II study enrolled
07/02/20 BMO Capital
Moderna mRNA platform supported by Pfizer vaccine data, says BMO Capital
SPY SPDR S&P 500 ETF Trust
$314.80 /

-2.81 (-0.88%)

06/04/20 Keefe Bruyette
Mattis rebuke 'wake up call' for stock market, says Keefe Bruyette
03/11/20 Goldman Sachs
Goldman Sachs believes the S&P 500 bull market will soon end
02/27/20 Keefe Bruyette
Stock market may rally Monday on 'Biden bounce,' Keefe Bruyette says
02/24/20
Dow Jones futures decline over 800 points ahead of today's open
SPX S&P 500
$0.00 /

+ (+0.00%)

06/04/20 Keefe Bruyette
Mattis rebuke 'wake up call' for stock market, says Keefe Bruyette
03/11/20 Goldman Sachs
Goldman Sachs believes the S&P 500 bull market will soon end
02/27/20 Keefe Bruyette
Stock market may rally Monday on 'Biden bounce,' Keefe Bruyette says
02/24/20
Dow Jones futures decline over 800 points ahead of today's open
NVAX Novavax
$104.46 /

+10.1 (+10.70%)

07/08/20
Fly Intel: Top five analyst downgrades
07/08/20 Ladenburg
Novavax downgraded to Neutral from Buy at Ladenburg
07/07/20 Cantor Fitzgerald
Novavax price target raised to $148 from $88 at Cantor Fitzgerald
07/02/20 B. Riley FBR
Novavax should be bought on weakness from Pfizer data, says B. Riley FBR
MRK Merck
$77.38 /

+0.64 (+0.83%)

06/30/20 SVB Leerink
Seattle Genetics price target raised to $167 from $155 at SVB Leerink
06/30/20 Oppenheimer
Seattle Genetics price target raised to $210 from $200 at Oppenheimer
06/25/20 Lake Street
Lake Street says Keytruda approval improves outlook for Checkpoint's cosibelimab
06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
SNY Sanofi
$50.96 /

+0.64 (+1.27%)

07/08/20 Piper Sandler
Piper upgrades Kiadis on 'platform validating' Sanofi deal
07/06/20 Citi
BioMarin price target raised to $148 from $105 at Citi
07/01/20 Roth Capital
Applied Genetic may attract Sanofi takeover interest, says Roth Capital
06/26/20 SunTrust
Translate Bio initiated with a Buy at SunTrust
GSK GlaxoSmithKline
$40.07 /

+0.16 (+0.40%)

12:02 Today UBS
UBS reiterates Buy on GSK as FDA belantamab docs are out
09:13 Today JPMorgan
Ideaya upgraded to Overweight on recent pullback at JPMorgan
06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
06/19/20 Barclays
Glaxo belantamab AdCom a surprise, supports cautious view, says Barclays
BNTX BioNTech
$77.73 /

+7.315 (+10.39%)

PFE Pfizer
$35.22 /

+1.38 (+4.08%)

INO Inovio
$25.57 /

+2.21 (+9.46%)

JNJ Johnson & Johnson
$145.30 /

+2.85 (+2.00%)

MRNA Moderna
$71.72 /

+9.15 (+14.62%)

SPY SPDR S&P 500 ETF Trust
$314.80 /

-2.81 (-0.88%)

SPX S&P 500
$0.00 /

+ (+0.00%)

NVAX Novavax
$104.46 /

+10.1 (+10.70%)

MRK Merck
$77.38 /

+0.64 (+0.83%)

SNY Sanofi
$50.96 /

+0.64 (+1.27%)

GSK GlaxoSmithKline
$40.07 /

+0.16 (+0.40%)

  • 19
    May
  • 12
    Feb
  • 06
    Feb
  • 10
    Oct
BNTX BioNTech
$77.73 /

+7.315 (+10.39%)

PFE Pfizer
$35.22 /

+1.38 (+4.08%)

INO Inovio
$25.57 /

+2.21 (+9.46%)

JNJ Johnson & Johnson
$145.30 /

+2.85 (+2.00%)

MRNA Moderna
$71.72 /

+9.15 (+14.62%)

SPY SPDR S&P 500 ETF Trust
$314.80 /

-2.81 (-0.88%)

SPX S&P 500
$0.00 /

+ (+0.00%)

NVAX Novavax
$104.46 /

+10.1 (+10.70%)

MRK Merck
$77.38 /

+0.64 (+0.83%)

SNY Sanofi
$50.96 /

+0.64 (+1.27%)

GSK GlaxoSmithKline
$40.07 /

+0.16 (+0.40%)

BNTX BioNTech
$77.73 /

+7.315 (+10.39%)

PFE Pfizer
$35.22 /

+1.38 (+4.08%)

INO Inovio
$25.57 /

+2.21 (+9.46%)

JNJ Johnson & Johnson
$145.30 /

+2.85 (+2.00%)

MRNA Moderna
$71.72 /

+9.15 (+14.62%)

NVAX Novavax
$104.46 /

+10.1 (+10.70%)

MRK Merck
$77.38 /

+0.64 (+0.83%)

SNY Sanofi
$50.96 /

+0.64 (+1.27%)

GSK GlaxoSmithKline
$40.07 /

+0.16 (+0.40%)

BNTX BioNTech
$77.73 /

+7.315 (+10.39%)

PFE Pfizer
$35.22 /

+1.38 (+4.08%)

INO Inovio
$25.57 /

+2.21 (+9.46%)

JNJ Johnson & Johnson
$145.30 /

+2.85 (+2.00%)

MRNA Moderna
$71.72 /

+9.15 (+14.62%)

SPY SPDR S&P 500 ETF Trust
$314.80 /

-2.81 (-0.88%)

SPX S&P 500
$0.00 /

+ (+0.00%)

NVAX Novavax
$104.46 /

+10.1 (+10.70%)

MRK Merck
$77.38 /

+0.64 (+0.83%)

SNY Sanofi
$50.96 /

+0.64 (+1.27%)

GSK GlaxoSmithKline
$40.07 /

+0.16 (+0.40%)

SPY SPDR S&P 500 ETF Trust
$314.80 /

-2.81 (-0.88%)

SPX S&P 500
$0.00 /

+ (+0.00%)

On The Fly
Fly Intel: After-Hours Movers » 18:58
07/13/20
07/13
18:58
07/13/20
18:58
INMB

INmune Bio

$8.74 /

+1.72 (+24.50%)

, VNDA

Vanda Pharmaceuticals

$11.37 /

-0.125 (-1.09%)

, FREQ

Frequency Therapeutics

$20.43 /

-2.4 (-10.51%)

, EW

Edwards Lifesciences

$67.18 /

-0.67 (-0.99%)

, BA

Boeing

$175.62 /

-2.825 (-1.58%)

, OSMT

Osmotica Pharmaceuticals

$7.71 /

-1.06 (-12.09%)

, ALT

Altimmune

$24.88 /

+2.56 (+11.47%)

Check out this evening's…

Open Full Text

ShowHide Related Items >><<
INMB INmune Bio
$8.74 /

+1.72 (+24.50%)

VNDA Vanda Pharmaceuticals
$11.37 /

-0.125 (-1.09%)

FREQ Frequency Therapeutics
$20.43 /

-2.4 (-10.51%)

EW Edwards Lifesciences
$67.18 /

-0.67 (-0.99%)

BA Boeing
$175.62 /

-2.825 (-1.58%)

OSMT Osmotica Pharmaceuticals
$7.71 /

-1.06 (-12.09%)

ALT Altimmune
$24.88 /

+2.56 (+11.47%)

INMB INmune Bio
$8.74 /

+1.72 (+24.50%)

03/12/20 H.C. Wainwright
INmune Bio price target lowered to $8 from $11 at H.C. Wainwright
03/11/20 Roth Capital
INmune makes progress in all programs, novel COVID-19 approach,says Roth Capital
12/18/19 Roth Capital
INmune Bio initiated with a Buy at Roth Capital
08/21/19
Fly Intel: Top five analyst initiations
VNDA Vanda Pharmaceuticals
$11.37 /

-0.125 (-1.09%)

06/09/20 Citi
Vanda downgraded to Neutral on FDA dispute at Citi
06/09/20 Citi
Vanda Pharmaceuticals downgraded to Neutral from Buy at Citi
03/16/20
Fly Intel: Top five analyst downgrades
03/16/20 Oppenheimer
Vanda Pharmaceuticals downgraded to Underperform at Oppenheimer on Hetlioz risks
FREQ Frequency Therapeutics
$20.43 /

-2.4 (-10.51%)

16:10 Today Oppenheimer
Frequency Therapeutics initiated with an Outperform at Oppenheimer
05/18/20 JPMorgan
JPMorgan downgrades Frequency Therapeutics on unclear data timelines
05/18/20 JPMorgan
Frequency Therapeutics downgraded to Neutral from Overweight at JPMorgan
10/28/19 JPMorgan
Frequency Therapeutics initiated with an Overweight at JPMorgan
EW Edwards Lifesciences
$67.18 /

-0.67 (-0.99%)

06/05/20 Piper Sandler
Post points to Edwards resuming recruiting for CLASP trial, says Piper Sandler
04/28/20 Wells Fargo
Edwards Lifesciences downgraded on sales growth gap at Wells Fargo
04/28/20 Wells Fargo
Edwards Lifesciences downgraded to Equal Weight from Overweight at Wells Fargo
04/27/20 Barclays
Edwards Lifesciences price target lowered to $155 from $165 at Barclays
BA Boeing
$175.62 /

-2.825 (-1.58%)

07/09/20
Emirates tells Bloomberg Boeing 777X likely to miss 2021 debut
07/08/20 Bernstein
Bernstein downgrades Spirit AeroSystems on slower delivery recovery
06/26/20
Fly Intel: Top five analyst downgrades
06/26/20 RBC Capital
Spirit AeroSystems initiated with an Outperform at RBC Capital
OSMT Osmotica Pharmaceuticals
$7.71 /

-1.06 (-12.09%)

07/10/20 SunTrust
Osmotica Pharmaceuticals price target raised to $11 from $8 at SunTrust
07/09/20 RBC Capital
Osmotica price target raised to $12 from $10 at RBC Capital
03/23/20 Wells Fargo
Wells Fargo downgrades Osmotica to Equal Weight, halves price target to $4
03/23/20 Wells Fargo
Osmotica Pharmaceuticals downgraded to Equal Weight from Overweight at Wells Fargo
ALT Altimmune
$24.88 /

+2.56 (+11.47%)

06/01/20 Roth Capital
Altimmune surprises with differentiated T-COVID study, says Roth Capital
05/06/20 Roth Capital
Novo data 'sets up the runway' for Altimmune, says Roth Capital
04/01/20
Roth Capital biotech analyst to hold an analyst/industry conference call
04/01/20
Roth Capital biotech analyst to hold an analyst/industry conference call
INMB INmune Bio
$8.74 /

+1.72 (+24.50%)

VNDA Vanda Pharmaceuticals
$11.37 /

-0.125 (-1.09%)

FREQ Frequency Therapeutics
$20.43 /

-2.4 (-10.51%)

EW Edwards Lifesciences
$67.18 /

-0.67 (-0.99%)

BA Boeing
$175.62 /

-2.825 (-1.58%)

OSMT Osmotica Pharmaceuticals
$7.71 /

-1.06 (-12.09%)

ALT Altimmune
$24.88 /

+2.56 (+11.47%)

  • 14
    Jul
  • 14
    Jul
  • 09
    Jan
  • 03
    Oct
EW Edwards Lifesciences
$67.18 /

-0.67 (-0.99%)

BA Boeing
$175.62 /

-2.825 (-1.58%)

VNDA Vanda Pharmaceuticals
$11.37 /

-0.125 (-1.09%)

EW Edwards Lifesciences
$67.18 /

-0.67 (-0.99%)

BA Boeing
$175.62 /

-2.825 (-1.58%)

OSMT Osmotica Pharmaceuticals
$7.71 /

-1.06 (-12.09%)

ALT Altimmune
$24.88 /

+2.56 (+11.47%)

FREQ Frequency Therapeutics
$20.43 /

-2.4 (-10.51%)

BA Boeing
$175.62 /

-2.825 (-1.58%)

ALT Altimmune
$24.88 /

+2.56 (+11.47%)

Periodicals
American Airlines to warn employees this week of possible furloughs, CNBC says » 18:50
07/13/20
07/13
18:50
07/13/20
18:50
AAL

American Airlines

$11.63 /

-0.3 (-2.51%)

American Airlines intends…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
AAL American Airlines
$11.63 /

-0.3 (-2.51%)

AAL American Airlines
$11.63 /

-0.3 (-2.51%)

07/09/20 Citi
Citi sees expectations for corporate travel rebound all but evaporating
06/17/20
Fly Intel: Top five analyst initiations
06/17/20 Seaport Global
American Airlines initiated with a Buy at Seaport Global
06/17/20 Cowen
American Airlines price target raised to $20 from $15 at Cowen
AAL American Airlines
$11.63 /

-0.3 (-2.51%)

  • 23
    Jun
AAL American Airlines
$11.63 /

-0.3 (-2.51%)

AAL American Airlines
$11.63 /

-0.3 (-2.51%)

AAL American Airlines
$11.63 /

-0.3 (-2.51%)

Periodicals
American Airlines emphases mask rules following Ted Cruz photo, Reuters says » 18:45
07/13/20
07/13
18:45
07/13/20
18:45
AAL

American Airlines

$11.63 /

-0.3 (-2.51%)

American Airlines said it…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
AAL American Airlines
$11.63 /

-0.3 (-2.51%)

AAL American Airlines
$11.63 /

-0.3 (-2.51%)

07/09/20 Citi
Citi sees expectations for corporate travel rebound all but evaporating
06/17/20
Fly Intel: Top five analyst initiations
06/17/20 Seaport Global
American Airlines initiated with a Buy at Seaport Global
06/17/20 Cowen
American Airlines price target raised to $20 from $15 at Cowen
AAL American Airlines
$11.63 /

-0.3 (-2.51%)

  • 23
    Jun
AAL American Airlines
$11.63 /

-0.3 (-2.51%)

AAL American Airlines
$11.63 /

-0.3 (-2.51%)

AAL American Airlines
$11.63 /

-0.3 (-2.51%)

Periodicals
Google offers to not use Fitbit health data for targeted ads, Reuters says » 18:41
07/13/20
07/13
18:41
07/13/20
18:41
GOOG

Alphabet

$1,511.65 /

-30.41 (-1.97%)

, GOOGL

Alphabet Class A

$1,510.81 /

-29.88 (-1.94%)

, FIT

Fitbit

$6.64 /

-0.175 (-2.57%)

Alphabet's (GOOG)…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
GOOG Alphabet
$1,511.65 /

-30.41 (-1.97%)

GOOGL Alphabet Class A
$1,510.81 /

-29.88 (-1.94%)

FIT Fitbit
$6.64 /

-0.175 (-2.57%)

GOOG Alphabet
$1,511.65 /

-30.41 (-1.97%)

06:38 Today Mizuho
Alphabet price target raised to $1,650 from $1,560 at Mizuho
06:24 Today Barclays
Alphabet price target raised to $1,600 from $1,400 at Barclays
07/09/20 Wedbush
Pinterest price target raised to $31 from $26 at Wedbush
07/07/20 BofA
Potential U.S. ban of TikTok could be tailwind to Snap engagement, says BofA
GOOGL Alphabet Class A
$1,510.81 /

-29.88 (-1.94%)

06:38 Today Mizuho
Alphabet price target raised to $1,650 from $1,560 at Mizuho
06:24 Today Barclays
Alphabet price target raised to $1,600 from $1,400 at Barclays
07/09/20 Wedbush
Pinterest price target raised to $31 from $26 at Wedbush
07/07/20 BofA
Potential U.S. ban of TikTok could be tailwind to Snap engagement, says BofA
FIT Fitbit
$6.64 /

-0.175 (-2.57%)

06/19/20 Deutsche Bank
Fitbit acquisition completing remains base case at Deutsche Bank
11/27/19 Deutsche Bank
Second Fitbit suitor should limit downside if deal breaks, says Deutsche Bank
11/06/19 DA Davidson
Sonos rallies after DA Davidson calls 'natural acquisition target' for Apple
11/04/19 DA Davidson
Fitbit downgraded to Neutral from Buy at DA Davidson
GOOG Alphabet
$1,511.65 /

-30.41 (-1.97%)

GOOGL Alphabet Class A
$1,510.81 /

-29.88 (-1.94%)

FIT Fitbit
$6.64 /

-0.175 (-2.57%)

GOOG Alphabet
$1,511.65 /

-30.41 (-1.97%)

GOOGL Alphabet Class A
$1,510.81 /

-29.88 (-1.94%)

FIT Fitbit
$6.64 /

-0.175 (-2.57%)

GOOG Alphabet
$1,511.65 /

-30.41 (-1.97%)

GOOGL Alphabet Class A
$1,510.81 /

-29.88 (-1.94%)

FIT Fitbit
$6.64 /

-0.175 (-2.57%)

GOOG Alphabet
$1,511.65 /

-30.41 (-1.97%)

GOOGL Alphabet Class A
$1,510.81 /

-29.88 (-1.94%)

FIT Fitbit
$6.64 /

-0.175 (-2.57%)

GOOG Alphabet
$1,511.65 /

-30.41 (-1.97%)

GOOGL Alphabet Class A
$1,510.81 /

-29.88 (-1.94%)

Upgrade
SKF AB double-upgraded to Buy from Sell at Goldman Sachs » 18:40
07/13/20
07/13
18:40
07/13/20
18:40
SKFRY

SKF AB

$0.00 /

+ (+0.00%)

Goldman Sachs analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SKFRY SKF AB
$0.00 /

+ (+0.00%)

07/08/20 JPMorgan
SKF AB price target raised to SEK 165 from SEK 160 at JPMorgan
06/26/20 SEB Equities
SKF AB upgraded to Buy from Hold at SEB Equities
06/12/20 Morgan Stanley
SKF AB price target raised to SEK 180 from SEK 130 at Morgan Stanley
06/03/20 Berenberg
SKF AB price target raised to SEK 200 from SEK 190 at Berenberg
Periodicals
White House to soon end audit deal over Chinese listings in U.S., Reuters says » 18:38
07/13/20
07/13
18:38
07/13/20
18:38
SPX

S&P 500

$0.00 /

+ (+0.00%)

, SPY

SPDR S&P 500 ETF Trust

$314.80 /

-2.81 (-0.88%)

, BABA

Alibaba

$251.71 /

-9.27 (-3.55%)

, JD

JD.com

$62.27 /

-3.33 (-5.08%)

, BIDU

Baidu

$127.96 /

-4.42 (-3.34%)

The White House intends…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
SPX S&P 500
$0.00 /

+ (+0.00%)

SPY SPDR S&P 500 ETF Trust
$314.80 /

-2.81 (-0.88%)

BABA Alibaba
$251.71 /

-9.27 (-3.55%)

JD JD.com
$62.27 /

-3.33 (-5.08%)

BIDU Baidu
$127.96 /

-4.42 (-3.34%)

SPX S&P 500
$0.00 /

+ (+0.00%)

06/04/20 Keefe Bruyette
Mattis rebuke 'wake up call' for stock market, says Keefe Bruyette
03/11/20 Goldman Sachs
Goldman Sachs believes the S&P 500 bull market will soon end
02/27/20 Keefe Bruyette
Stock market may rally Monday on 'Biden bounce,' Keefe Bruyette says
02/24/20
Dow Jones futures decline over 800 points ahead of today's open
SPY SPDR S&P 500 ETF Trust
$314.80 /

-2.81 (-0.88%)

06/04/20 Keefe Bruyette
Mattis rebuke 'wake up call' for stock market, says Keefe Bruyette
03/11/20 Goldman Sachs
Goldman Sachs believes the S&P 500 bull market will soon end
02/27/20 Keefe Bruyette
Stock market may rally Monday on 'Biden bounce,' Keefe Bruyette says
02/24/20
Dow Jones futures decline over 800 points ahead of today's open
BABA Alibaba
$251.71 /

-9.27 (-3.55%)

07/09/20
Fly Intel: Top five analyst initiations
07/09/20 Needham
Alibaba initiated with a Buy at Needham
06/19/20 Barclays
Alibaba price target raised to $270 from $260 at Barclays
06/19/20 Morgan Stanley
6.18 promotion in China released pent-up buying demand, says Morgan Stanley
JD JD.com
$62.27 /

-3.33 (-5.08%)

06/30/20 Mizuho
JD.com price target raised to $75 from $62 at Mizuho
06/19/20 Barclays
JD.com price target raised to $65 from $59 at Barclays
06/19/20 Morgan Stanley
6.18 promotion in China released pent-up buying demand, says Morgan Stanley
06/18/20 Goldman Sachs
JD.com price target raised to $71 from $59 at Goldman Sachs
BIDU Baidu
$127.96 /

-4.42 (-3.34%)

07/02/20 Loop Capital
iQIYI price target raised to $23 from $20 at Loop Capital
06/15/20 Mizuho
Baidu valuation 'compelling' on overstated concerns, says Mizuho
05/20/20 KeyBanc
Baidu price target raised to $145 from $136 at KeyBanc
05/20/20 HSBC
Baidu price target raised to $132 from $120 at HSBC
SPX S&P 500
$0.00 /

+ (+0.00%)

SPY SPDR S&P 500 ETF Trust
$314.80 /

-2.81 (-0.88%)

BABA Alibaba
$251.71 /

-9.27 (-3.55%)

JD JD.com
$62.27 /

-3.33 (-5.08%)

BIDU Baidu
$127.96 /

-4.42 (-3.34%)

SPX S&P 500
$0.00 /

+ (+0.00%)

SPY SPDR S&P 500 ETF Trust
$314.80 /

-2.81 (-0.88%)

BABA Alibaba
$251.71 /

-9.27 (-3.55%)

JD JD.com
$62.27 /

-3.33 (-5.08%)

BIDU Baidu
$127.96 /

-4.42 (-3.34%)

BABA Alibaba
$251.71 /

-9.27 (-3.55%)

JD JD.com
$62.27 /

-3.33 (-5.08%)

BIDU Baidu
$127.96 /

-4.42 (-3.34%)

SPX S&P 500
$0.00 /

+ (+0.00%)

SPY SPDR S&P 500 ETF Trust
$314.80 /

-2.81 (-0.88%)

BABA Alibaba
$251.71 /

-9.27 (-3.55%)

JD JD.com
$62.27 /

-3.33 (-5.08%)

BIDU Baidu
$127.96 /

-4.42 (-3.34%)

SPX S&P 500
$0.00 /

+ (+0.00%)

SPY SPDR S&P 500 ETF Trust
$314.80 /

-2.81 (-0.88%)

Syndicate
nCino 8.06M share IPO priced at $31.00 » 18:13
07/13/20
07/13
18:13
07/13/20
18:13
NCNO

nCino

$0.00 /

+ (+0.00%)

The deal size was…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
  • 14
    Jul
NCNO nCino
$0.00 /

+ (+0.00%)

Hot Stocks
Galera Therapeutics completes enrollment of ph1b/2a clinical trial of GC4419 » 17:47
07/13/20
07/13
17:47
07/13/20
17:47
GRTX

Galera Therapeutics

$7.35 /

+0.22 (+3.09%)

Galera Therapeutics…

Galera Therapeutics announced that it has completed patient enrollment in its pilot Phase 1b/2a safety and anti-cancer efficacy clinical trial of avasopasem manganese in combination with stereotactic body radiation therapy in patients with locally advanced pancreatic cancer. Galera's investigational, highly selective small molecule superoxide dismutase mimetics are designed to rapidly and selectively convert superoxide to hydrogen peroxide and oxygen. These dismutase mimetics have potential anti-cancer synergy supported by positive results in multiple preclinical models. The randomized Phase 1b/2a trial is evaluating the safety, progression-free survival and overall response rate of GC4419 in combination with SBRT, compared with SBRT and placebo, in LAPC patients. The trial is also assessing safety and tolerability to determine the recommended dose of SBRT when combined with GC4419 or placebo.

ShowHide Related Items >><<
GRTX Galera Therapeutics
$7.35 /

+0.22 (+3.09%)

GRTX Galera Therapeutics
$7.35 /

+0.22 (+3.09%)

12/02/19 BTIG
Galera Therapeutics initiated with a Buy at BTIG
12/02/19 Credit Suisse
Galera Therapeutics initiated with a Neutral at Credit Suisse
12/02/19 Citi
Galera Therapeutics initiated with a Buy at Citi
12/02/19 BofA
Galera Therapeutics initiated with a Buy at BofA/Merrill
GRTX Galera Therapeutics
$7.35 /

+0.22 (+3.09%)

  • 07
    Nov
Conference/Events
Goldman Sachs Global FX analyst to hold analyst/industry conference call » 17:38
07/13/20
07/13
17:38
07/13/20
17:38

Co-Head of Global FX,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Periodicals
Ford to unveil new Bronco on Monday night, WSJ reports » 17:38
07/13/20
07/13
17:38
07/13/20
17:38
F

Ford

$6.07 /

-0.025 (-0.41%)

, FCAU

Fiat Chrysler

$10.07 /

-0.045 (-0.45%)

For the first time in 24…

For the first time in 24 years, Ford (F) intends to unveil a new Bronco on Monday night, the company's latest attempt to carve into a share of Jeep's (FCAU) dominant position in the off-road sector, the Wall Street Journal's Mike Colias reports. The Bronco would be coming off the sidelines at an interesting time, as U.S. vehicle sales are expected to contract approximately 25% in 2020 largely due to the COVID-19 pandemic, Colias says, citing analyst projections. Reference Link

ShowHide Related Items >><<
FCAU Fiat Chrysler
$10.07 /

-0.045 (-0.45%)

F Ford
$6.07 /

-0.025 (-0.41%)

F Ford
$6.07 /

-0.025 (-0.41%)

06/25/20 Morgan Stanley
Talks with Ford dealer highlight inventory risk, says Morgan Stanley
06/24/20 Morgan Stanley
GM electric vehicle business could be worth $100B, says Morgan Stanley
06/19/20 JPMorgan
Ford price target raised to $7 from $6 at JPMorgan
06/18/20 Jefferies
Jefferies raises price targets for Ford, GM and FCA on balance sheet de-risking
FCAU Fiat Chrysler
$10.07 /

-0.045 (-0.45%)

06/30/20 UBS
Fiat Chrysler price target raised to EUR 9 from EUR 6 at UBS
06/22/20 Redburn
Fiat Chrysler upgraded to Buy from Neutral at Redburn
FCAU Fiat Chrysler
$10.07 /

-0.045 (-0.45%)

F Ford
$6.07 /

-0.025 (-0.41%)

FCAU Fiat Chrysler
$10.07 /

-0.045 (-0.45%)

F Ford
$6.07 /

-0.025 (-0.41%)

FCAU Fiat Chrysler
$10.07 /

-0.045 (-0.45%)

F Ford
$6.07 /

-0.025 (-0.41%)

FCAU Fiat Chrysler
$10.07 /

-0.045 (-0.45%)

F Ford
$6.07 /

-0.025 (-0.41%)

Conference/Events
Goldman Sachs semiconductors analyst to hold an analyst/industry conference call » 17:33
07/13/20
07/13
17:33
07/13/20
17:33

US Semi Analyst Hari and…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Syndicate
Hycroft files to sell 60.9M shares of common stock, 13.5M warrants for holders  17:32
07/13/20
07/13
17:32
07/13/20
17:32
HYMC

Hycroft Mining

$11.05 /

+0.36 (+3.37%)

 
Syndicate
Entera Bio files $100M mixed securities shelf  17:29
07/13/20
07/13
17:29
07/13/20
17:29
ENTX

Entera Bio

$1.84 /

+0.04 (+2.22%)

 
ShowHide Related Items >><<
ENTX Entera Bio
$1.84 /

+0.04 (+2.22%)

Recommendations
Roth Capital positive on Turning Point Therapeutics appointment of Partridge » 17:28
07/13/20
07/13
17:28
07/13/20
17:28
TPTX

Turning Point Therapeutics

$60.02 /

-0.5 (-0.83%)

Roth Capital analyst…

Roth Capital analyst Zegbeh Jallah keeps his Buy rating and $75 price target on Turning Point Therapeutics, saying the company's appointment of Andrew Partridge as Executive VP and Chief Commercial Officer represents a "strong addition to the team". The analyst is positive on the executive's over 20 years of pharmaceutical marketing and sales experience along with a strong track record of global commercial launches and multibillion-dollar marketing operations.

ShowHide Related Items >><<
TPTX Turning Point Therapeutics
$60.02 /

-0.5 (-0.83%)

TPTX Turning Point Therapeutics
$60.02 /

-0.5 (-0.83%)

07/10/20
Fly Intel: Top five analyst initiations
07/09/20 Oppenheimer
Oppenheimer starts precision oncology 'upstart' Turning Point at Outperform
07/09/20 Roth Capital
Turning Point agreement with Zai Lab favorable, says Roth Capital
07/09/20 Oppenheimer
Turning Point Therapeutics initiated with an Outperform at Oppenheimer
TPTX Turning Point Therapeutics
$60.02 /

-0.5 (-0.83%)

  • 19
    May
  • 06
    Sep
Hot Stocks
Mohawk sinks 10% to $68.64 after announcing Class Action lawsuit  17:26
07/13/20
07/13
17:26
07/13/20
17:26
MHK

Mohawk

$76.59 /

+6.06 (+8.59%)

 
ShowHide Related Items >><<
MHK Mohawk
$76.59 /

+6.06 (+8.59%)

MHK Mohawk
$76.59 /

+6.06 (+8.59%)

07/10/20 Jefferies
Mohawk could see short-lived relief rally after flooring data, says Jefferies
07/09/20 Stifel
Stifel says 'difficult if not impossible to opine' on Mohawk allegations
07/09/20 JPMorgan
Allegations in lawsuit to create overhang on Mohawk shares, says JPMorgan
07/09/20 SunTrust
Mohawk quiet period hinders lawsuit response, says SunTrust
MHK Mohawk
$76.59 /

+6.06 (+8.59%)

MHK Mohawk
$76.59 /

+6.06 (+8.59%)

MHK Mohawk
$76.59 /

+6.06 (+8.59%)

MHK Mohawk
$76.59 /

+6.06 (+8.59%)

Hot Stocks
Triumph Group names Tom Blakely group CTO » 17:26
07/13/20
07/13
17:26
07/13/20
17:26
TGI

Triumph Group

$8.09 /

-0.165 (-2.00%)

Triumph Group announced…

Triumph Group announced that Tom Blakely will join the company as Chief Technology Officer, reporting to Vice President of Operations, Nick Drazic. Blakely has led the development, certification, and transition to production of dozens of advanced military and commercial aircraft as well as complex subsystems and components over the last four decades. In this new role, Blakely will chair Triumph's Innovation and Technology Council and oversee technical matters across the company's 36 factories including both original equipment and aftermarket contracts. Blakely will also prioritize and manage the company's research and development efforts as it develops intellectual property in alignment with its business strategy. "Development of proprietary products and processes is key to Triumph's growth on new platforms and profitability," said Drazic. "As we expand our military backlog, Tom will play a critical role in partnering with our military customers to offer solutions for current and future platforms."

ShowHide Related Items >><<
TGI Triumph Group
$8.09 /

-0.165 (-2.00%)

TGI Triumph Group
$8.09 /

-0.165 (-2.00%)

03/20/20 BofA
BofA double downgrades Triumph, slashes price target amid COVID-19 impact
03/20/20 BofA
Triumph Group downgraded to Underperform from Buy at BofA
03/11/20 Goldman Sachs
Goldman cuts targets across Aerospace coverage for COVID-19 impact
08/23/19
Fly Intel: Top five analyst downgrades
TGI Triumph Group
$8.09 /

-0.165 (-2.00%)

TGI Triumph Group
$8.09 /

-0.165 (-2.00%)

Conference/Events
Susquehanna technology analyst to hold analyst/industry conference call » 17:25
07/13/20
07/13
17:25
07/13/20
17:25
AMD

AMD

$53.58 /

-2.31 (-4.13%)

Technology Analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
AMD AMD
$53.58 /

-2.31 (-4.13%)

AMD AMD
$53.58 /

-2.31 (-4.13%)

06/19/20 Jefferies
AMD still taking share in CPU-only cloud instances, says Jefferies
06/15/20 Piper Sandler
AMD well positioned for continued market share gains, says Piper Sandler
06/15/20 Nomura Instinet
AMD on pace for 20%-30% sales growth in 2020, says Nomura Instinet
06/12/20 Rosenblatt
Rosenblatt says Jim Keller's departure from Intel a 'big deal'
AMD AMD
$53.58 /

-2.31 (-4.13%)

AMD AMD
$53.58 /

-2.31 (-4.13%)

AMD AMD
$53.58 /

-2.31 (-4.13%)

AMD AMD
$53.58 /

-2.31 (-4.13%)

Hot Stocks
Mohawk says Class Action lawsuit filed against company » 17:24
07/13/20
07/13
17:24
07/13/20
17:24
MHK

Mohawk

$76.59 /

+6.06 (+8.59%)

In a regulatory filing,…

In a regulatory filing, Mohawk said, "As we manage through the current economic disruption, Mohawk is well positioned with a strong balance sheet and limited debt. We have recently issued over $1 billion of long term bonds to strengthen our ability to strategically invest and better position Mohawk for the future. Our operations are improving as countries adapt to Covid-19. On June 29, 2020, an Amended Class Action Complaint for violations of federal securities laws was filed against Mohawk and its CEO Jeff Lorberbaum in the Northern District of Georgia. The complaint alleges that the company (1) engaged in fabricating revenues by attempting delivery to customers that were closed and recognizing these attempts as sales; (2) overproduced product to report higher operating margins and maintained significant inventory that was not salable; and (3) valued certain inventory improperly or improperly delivered inventory with knowledge that it was defective and customers would return it. The company intends to vigorously defend itself in the lawsuit." On June 25, 2020, the company received subpoenas issued by the U.S. Attorney's Office for the Northern District of Georgia and the U.S. Securities and Exchange Commission on topics similar to those raised by the amended complaint. The company is cooperating with those authorities.

ShowHide Related Items >><<
MHK Mohawk
$76.59 /

+6.06 (+8.59%)

MHK Mohawk
$76.59 /

+6.06 (+8.59%)

07/10/20 Jefferies
Mohawk could see short-lived relief rally after flooring data, says Jefferies
07/09/20 Stifel
Stifel says 'difficult if not impossible to opine' on Mohawk allegations
07/09/20 JPMorgan
Allegations in lawsuit to create overhang on Mohawk shares, says JPMorgan
07/09/20 SunTrust
Mohawk quiet period hinders lawsuit response, says SunTrust
MHK Mohawk
$76.59 /

+6.06 (+8.59%)

MHK Mohawk
$76.59 /

+6.06 (+8.59%)

MHK Mohawk
$76.59 /

+6.06 (+8.59%)

MHK Mohawk
$76.59 /

+6.06 (+8.59%)

Hot Stocks
Invitae CMO sells 29.8K shares of common stock » 17:24
07/13/20
07/13
17:24
07/13/20
17:24
NVTA

Invitae

$32.78 /

-0.72 (-2.15%)

In a regulatory filing,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
NVTA Invitae
$32.78 /

-0.72 (-2.15%)

NVTA Invitae
$32.78 /

-0.72 (-2.15%)

07/01/20 Benchmark
Benchmark says Invitae 'ahead of itself,' downgrades to Hold after run-up
07/01/20 Benchmark
Invitae downgraded to Hold from Buy at Benchmark
06/26/20 Cowen
Invitae price target raised to $35 from $18 at Cowen
06/22/20 Piper Sandler
Invitae deal for ArcherDx presents little threat to Natera, says Piper Sandler
NVTA Invitae
$32.78 /

-0.72 (-2.15%)

  • 02
    Apr
NVTA Invitae
$32.78 /

-0.72 (-2.15%)

NVTA Invitae
$32.78 /

-0.72 (-2.15%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.